2022/03/10
Digital Health from a Healthcare Perspective (Part 4)
FRONTEO is developing a “conversational dementia diagnostic support AI program” that screens for cognitive dysfunction using AI and natural language. This program is the first linguistic AI program medical device in Japan, and clinical trials started in April 2021. Mr. Keisuke Harada, who has ten years of experience in pharmaceutical clinical development, will explain this AI program.
Mr. Keisuke Harada
ジャーナル84号のトピックは、Aetion社 (RWE)、CytoReason社 (AI創薬)、Pear Therapeutics社 (PDTx)、Headspace Health社 (メンタルヘルスケア)、Tidepool (糖尿病ケア)、Akili Interactive社 (PDTx)、Amazon Pharmacy社 など
LSMIP Editorial Office
Kazunori Seto M.D.
Nanao Amano
Natsu Ono M.D.
Dr. Shinpaku